Revvity, a Diagnostics and Life Sciences company, recently announced the country launch of its T-SPOT.TB test for latent TB screening, at MICROCON in Lucknow.
Revvity’s T-SPOT.TB is the only FDA-approved, commercially available IGRA (interferon-gamma release assay) based on the ELISPOT technology. This technology includes the isolation, washing, and counting of peripheral blood mononuclear cells (PBMCs) from whole blood to standardize the test and provide reproducible results for reliable detection — even in challenging-to-screen groups, such as the immunosuppressed.
Shripad Joshi, President, India & South Asia at Revvity said: “With approximately 40% of the Indian population being infected with latent TB, detecting the infection before it progresses to active disease, which is symptomatic and infectious, is paramount. We recognize the critical role that collaboration between the public and private sectors plays in the Government’s mission of eradicating TB by 2025. As a result, we are committed to working closely with the Indian healthcare sector to integrate our reliable, single-visit T-SPOT.TB test into the country’s existing healthcare infrastructure, increasing accessibility and affordability of latent TB screening.
Joshi also said that they have 20 years’ experience in TB screening and have been collaborating with several healthcare systems around the world.
“We are now thrilled to be able to start equipping healthcare professionals in India with advanced screening tools that can support the government’s mission effectively, decrease costs associated with treating active or drug-resistant TB, and more importantly, saving lives,” he added.
